Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Warner Music Group Corp (WMG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Warner Music Group Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while Warner Music Group Corp trades at $28.94 (market cap $14.83B). The key difference: Warner Music Group Corp is far larger — about 3.3× ACADIA Pharmaceuticals Inc.'s market cap, and Warner Music Group Corp pays a 2.67% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | WMG | |
|---|---|---|
Market Cap | $4.49B | $14.83B |
Sector | Health | Media |
52-Week High | $28.06 | $34.72 |
52-Week Low | $20.06 | $23.65 |
Enterprise Value | $3.69B | $19.03B |
Dividend Yield | — | 2.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Warner Music Group (WMG) trades at $28.44, up 0.57% today, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $0.35, beating expectations, and announced the acquisition of Sureel AI to strengthen IP management. Financials show revenue growth to $6.71B in 2025, though net income margin declined to 5.44%. Valuation ratios include a P/E of 32.62 and P/S of 2.01, with a consensus analyst price target of $40.40 indicating significant upside potential.
WMG presents a mixed outlook: strong analyst support (66.7% buy ratings) and strategic AI investments offer growth opportunities, but bearish technicals, declining net margins, and competitive pressures pose risks. The stock's current price near support at $27 suggests cautious investor sentiment, with earnings consistency and margin improvement key to unlocking upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
